Smith Karen L.

Director at Aurinia Pharmaceuticals Inc. · on record since Aug 21, 2023
Director at Context Therapeutics Inc. · on record since Sep 5, 2024
Director at SKYE INTERNATIONAL, INC · on record since Apr 2, 2026
EVP, R&D and CMO at JAZZ PHARMACEUTICALS INC · on record since May 12, 2017
Director at Sucampo Pharmaceuticals, Inc. · on record since Jul 27, 2017
Director at ACCELERON PHARMA INC · on record since Nov 15, 2017
Director at SANGAMO BIOSCIENCES INC · on record since Jun 28, 2018
Director at ALTIRIS INC · on record since Mar 5, 2019
EVP, Chief Medical Officer at Emergent BioSolutions Inc. · on record since May 28, 2020
Chief Medical Officer at CRITICAL THERAPEUTICS INC · on record since May 27, 2022
Director at Talaris Therapeutics, Inc. · on record since May 17, 2022
Chief Medical Officer at Quince Therapeutics, Inc. · on record since Feb 2, 2023

Insider trading activity of Smith Karen L.

Transactions on record: 117; since May 13, 2015

Open-market buys: 4; $250K

Open-market sells: 7; $2.9M

Companies traded: 12; last filing Jun 26, 2026

Figures computed from official regulatory filings — methodology.

Companies where Smith Karen L. has traded

Context Therapeutics Inc.3 tx · Jun 26, 2026
SKYE INTERNATIONAL, INC5 tx · Apr 2, 2026
SANGAMO BIOSCIENCES INC18 tx · Jun 16, 2025
Aurinia Pharmaceuticals Inc.7 tx · $44.2K · Nov 25, 2024
Talaris Therapeutics, Inc.3 tx · Jun 14, 2023
Quince Therapeutics, Inc.1 tx · Feb 2, 2023
CRITICAL THERAPEUTICS INC4 tx · May 27, 2022
ALTIRIS INC13 tx · $711K · May 26, 2022
ACCELERON PHARMA INC33 tx · $3.6M · Nov 22, 2021

Track record of Smith Karen L.

Insufficient history for a statistical track record (fewer than 5 open-market buys).

Transaction history of Smith Karen L.

Co-insiders of Smith Karen L.

This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →

Company	Filed	Type	Qty	Price	Value · USD	Src
Context Therapeutics Inc.	Jun 26, 2026	AwardD	45,000	0.00 USD	—	SEC
SKYE INTERNATIONAL, INC	Apr 2, 2026	AwardD	75,000	0.00 USD	$0	SEC
SKYE INTERNATIONAL, INC	Feb 9, 2026	AwardD	35,000	0.00 USD	$0	SEC
SANGAMO BIOSCIENCES INC	Jun 16, 2025	AwardD	50,000	0.00 USD	$0	SEC
SANGAMO BIOSCIENCES INC	Jun 16, 2025	Award	25,000	0.00 USD	$0	SEC
Context Therapeutics Inc.	Jun 12, 2025	AwardD	123,500	0.00 USD	$0	SEC
SKYE INTERNATIONAL, INC	Feb 26, 2025	AwardD	35,000	0.00 USD	$0	SEC
Aurinia Pharmaceuticals Inc.	Nov 25, 2024	Award	12,135	0.00 USD	$0	SEC
Aurinia Pharmaceuticals Inc.	Nov 25, 2024	AwardD	18,641	0.00 USD	$0	SEC
Aurinia Pharmaceuticals Inc.	Nov 12, 2024	Exercise	17,913	—	—	SEC
Aurinia Pharmaceuticals Inc.	Nov 12, 2024	ExerciseD	-17,913	0.00 USD	$0	SEC
Aurinia Pharmaceuticals Inc.	Nov 12, 2024	Sell	-5,241	8.43 USD	$44.2K	SEC
SKYE INTERNATIONAL, INC	Oct 30, 2024	AwardD	70,000	0.00 USD	$0	SEC
Context Therapeutics Inc.	Sep 5, 2024	AwardD	19,315	0.00 USD	$0	SEC
SKYE INTERNATIONAL, INC	Jul 5, 2024	AwardD	40,000	0.00 USD	$0	SEC
SANGAMO BIOSCIENCES INC	Jun 6, 2024	AwardD	50,000	0.00 USD	$0	SEC
SANGAMO BIOSCIENCES INC	Jun 6, 2024	Award	25,000	0.00 USD	$0	SEC
Aurinia Pharmaceuticals Inc.	Aug 21, 2023	AwardD	17,913	0.00 USD	$0	SEC
Aurinia Pharmaceuticals Inc.	Aug 21, 2023	AwardD	28,959	0.00 USD	$0	SEC
Talaris Therapeutics, Inc.	Jun 14, 2023	AwardD	20,500	0.00 USD	$0	SEC
SANGAMO BIOSCIENCES INC	Jun 5, 2023	Award	13,900	0.00 USD	$0	SEC
SANGAMO BIOSCIENCES INC	Jun 5, 2023	AwardD	27,750	0.00 USD	$0	SEC
Quince Therapeutics, Inc.	Feb 2, 2023	AwardD	225,000	0.00 USD	$0	SEC
Talaris Therapeutics, Inc.	Jun 13, 2022	AwardD	14,501	0.00 USD	$0	SEC
CRITICAL THERAPEUTICS INC	May 27, 2022	Award	170,354	0.00 USD	$0	SEC

Company	Filed	Type	Qty	Price	Value · USD	Src
Context Therapeutics Inc.	Jun 26, 2026	AwardD	45,000	0.00 USD	—	SEC
SKYE INTERNATIONAL, INC	Apr 2, 2026	AwardD	75,000	0.00 USD	$0	SEC
SKYE INTERNATIONAL, INC	Feb 9, 2026	AwardD	35,000	0.00 USD	$0	SEC
SANGAMO BIOSCIENCES INC	Jun 16, 2025	AwardD	50,000	0.00 USD	$0	SEC
SANGAMO BIOSCIENCES INC	Jun 16, 2025	Award	25,000	0.00 USD	$0	SEC
Context Therapeutics Inc.	Jun 12, 2025	AwardD	123,500	0.00 USD	$0	SEC
SKYE INTERNATIONAL, INC	Feb 26, 2025	AwardD	35,000	0.00 USD	$0	SEC
Aurinia Pharmaceuticals Inc.	Nov 25, 2024	Award	12,135	0.00 USD	$0	SEC
Aurinia Pharmaceuticals Inc.	Nov 25, 2024	AwardD	18,641	0.00 USD	$0	SEC
Aurinia Pharmaceuticals Inc.	Nov 12, 2024	Exercise	17,913	—	—	SEC
Aurinia Pharmaceuticals Inc.	Nov 12, 2024	ExerciseD	-17,913	0.00 USD	$0	SEC
Aurinia Pharmaceuticals Inc.	Nov 12, 2024	Sell	-5,241	8.43 USD	$44.2K	SEC
SKYE INTERNATIONAL, INC	Oct 30, 2024	AwardD	70,000	0.00 USD	$0	SEC
Context Therapeutics Inc.	Sep 5, 2024	AwardD	19,315	0.00 USD	$0	SEC
SKYE INTERNATIONAL, INC	Jul 5, 2024	AwardD	40,000	0.00 USD	$0	SEC
SANGAMO BIOSCIENCES INC	Jun 6, 2024	AwardD	50,000	0.00 USD	$0	SEC
SANGAMO BIOSCIENCES INC	Jun 6, 2024	Award	25,000	0.00 USD	$0	SEC
Aurinia Pharmaceuticals Inc.	Aug 21, 2023	AwardD	17,913	0.00 USD	$0	SEC
Aurinia Pharmaceuticals Inc.	Aug 21, 2023	AwardD	28,959	0.00 USD	$0	SEC
Talaris Therapeutics, Inc.	Jun 14, 2023	AwardD	20,500	0.00 USD	$0	SEC
SANGAMO BIOSCIENCES INC	Jun 5, 2023	Award	13,900	0.00 USD	$0	SEC
SANGAMO BIOSCIENCES INC	Jun 5, 2023	AwardD	27,750	0.00 USD	$0	SEC
Quince Therapeutics, Inc.	Feb 2, 2023	AwardD	225,000	0.00 USD	$0	SEC
Talaris Therapeutics, Inc.	Jun 13, 2022	AwardD	14,501	0.00 USD	$0	SEC
CRITICAL THERAPEUTICS INC	May 27, 2022	Award	170,354	0.00 USD	$0	SEC